Peter Mol

Professor Drug Regulatory Science

University Medical Center Groningen

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Mol is a Professor of Drug Regulatory Science at the University Medical Center Groningen in the Netherlands. His research primarily focuses on the utilization of real-world data in regulatory decision-making, patient registry management, and the impact of digital health technologies on patient outcomes. Recent publications include studies on cardiac resynchronization therapy, beta-blockers in heart failure patients, and the integration of patient-reported outcomes in cancer treatment regulations.

Articles (24)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (11)

Petra Denig

NETHERLANDS

View details

Jesús María Hernández-Rivas

Universidad de Salamanca

SPAIN

View details

Walter Van Dyck

Visiting Professor

KU Leuven

BELGIUM

View details

Anna Glaser

Karolinska Institutet

SWEDEN

View details

Hubert G. M. Leufkens

NETHERLANDS

View details

Björn Wettermark

SWEDEN

View details

Kieran Breen

Head of Research and Decelopment

UNITED KINGDOM

View details

Christine Hallgreen

Københavns Universitet

DENMARK

View details

Carla Torre

Universidade de Aveiro

PORTUGAL

View details

Cecilia LInde

Karolinska University Hospital

SWEDEN

View details

Raffaele Scorza

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Mol

Research Interests

Explore related searches

Contact this professor

About

Articles (24)

Navigating the Real World: A Scoping Review of Structured Frameworks to Effectively Identify, Evaluate, and Select Real‐World Data Sources for Fit‐for‐Purpose Studies

Timing of Cardiac Resynchronization Therapy Following Stable Medical Therapy in Patients With Heart Failure

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an <scp>HMA</scp>/<scp>EMA</scp> Multistakeholder Workshop

Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease

Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024

Letter to the editor re: fatal intracranial haemorrhage after belzutifan initiation

Stakeholders’ Perspectives Toward the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

Insights from the European Medicines Agency on digital health technology derived endpoints

Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment

Long-term follow-up after authorization of gene therapy

The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report

Real‐World Evidence to Support EU Regulatory Decision Making—Results From a Pilot of Regulatory Use Cases

Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy

Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?

Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands

Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross‐Sectional Analysis of Centralized Procedures in the European Union 2010–2020

Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach

Attention for sex in COVID-19 trials: a review of regulatory dossiers

Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders

Collaborators (11)

Petra Denig

Jesús María Hernández-Rivas

Walter Van Dyck

Anna Glaser

Hubert G. M. Leufkens

Björn Wettermark

Kieran Breen

Christine Hallgreen

Carla Torre

Cecilia LInde

Raffaele Scorza

Make your next move.